Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Imperial College London
Orano Med LLC
Xencor, Inc.
Kaiser Permanente
Duke University
Washington University School of Medicine
MBrace Therapeutics
University of Colorado, Denver
Roswell Park Cancer Institute
Unity Health Toronto
City of Hope Medical Center